文献速递浆细胞疾病造血干细胞移植与细胞治疗

Ide-cel对比标准方案治疗三类暴露的复发难治多发性骨髓瘤:KarMMa-3试验更新分析

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.
PubMed 文献 · Blood · 2024-01-01

KarMMa-3三期试验将三类暴露的复发难治多发性骨髓瘤患者按2:1随机分配至ide-cel组或标准方案组。最终PFS分析(中位随访30.9个月)显示ide-cel组中位PFS为13.8个月,标准方案组为4.4个月(HR 0.49,95%CI 0.38-0.63);ORR分别为71%和42%,完全缓解率分别为44%和5%。

要点

  • 最终PFS分析显示ide-cel组中位PFS 13.8个月,标准方案组4.4个月(HR 0.49,95%CI 0.38-0.63)
  • ORR为71% vs 42%,完全缓解为44% vs 5%,ide-cel优于标准方案
  • 标准方案组56%患者疾病进展后交叉至ide-cel,混淆OS解读;校正交叉后预设分析显示OS倾向ide-cel

核心结论

  • 在三类暴露的复发难治多发性骨髓瘤中,ide-cel较标准方案持续改善PFS和ORR,未报告新的安全信号,显示持续有利的获益-风险特征。

研究设计与样本

  • KarMMa-3为三期随机对照试验,纳入三类暴露的复发难治多发性骨髓瘤且既往接受2至4线治疗的患者,按2:1随机分配至ide-cel组或标准方案组。
  • 最终PFS分析时中位随访30.9个月,试验注册号为NCT03651128。

主要发现

  • 最终PFS分析中,ide-cel组中位PFS为13.8个月,标准方案组为4.4个月(HR 0.49,95%CI 0.38-0.63)。
  • 无论既往治疗线数如何均观察到ide-cel较标准方案的PFS获益,既往2线治疗后获益最大(16.2个月 vs 4.8个月)。
  • ORR为ide-cel组71% vs 标准方案组42%,完全缓解为44% vs 5%。
  • OS中期分析时,ide-cel组中位OS为41.4个月(95%CI 30.9至未达到),标准方案组为37.9个月(95%CI 23.4至未达到)(HR 1.01,95%CI 0.73-1.40);两组中位OS均长于历史数据(9-22个月)。
  • 标准方案组56%患者在疾病进展后交叉至ide-cel,混淆OS解读;两项校正交叉的预设分析显示OS倾向ide-cel。

关键数值与推荐

  • 最终PFS分析:ide-cel组中位PFS 13.8个月 vs 标准方案组4.4个月,HR 0.49(95%CI 0.38-0.63)。
  • ORR:ide-cel组71% vs 标准方案组42%;完全缓解:ide-cel组44% vs 标准方案组5%。
  • OS中期分析:ide-cel组中位OS 41.4个月(95%CI 30.9至未达到)vs 标准方案组37.9个月(95%CI 23.4至未达到),HR 1.01(95%CI 0.73-1.40)。
  • 既往2线治疗后亚组中位PFS:ide-cel组16.2个月 vs 标准方案组4.8个月。
  • 标准方案组交叉至ide-cel的比例为56%。

临床怎么用

  • 试验强调个体化桥接治疗的重要性,以确保ide-cel生产期间充分的疾病控制。
  • ide-cel较标准方案改善患者报告结局。
  • 原文未据此给出其他推荐。

局限性

  • 患者中心设计允许标准方案组疾病进展后交叉至ide-cel(56%),混淆总生存解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Outcomes are poor in triple-class-exposed (TCE) relapsed and refractory multiple myeloma (R/RMM). In the phase 3 KarMMa-3 trial, patients with TCE R/RMM and 2 to 4 prior regimens were randomized 2:1 to idecabtagene vicleucel (ide-cel) or standard regimens (SRs). An interim analysis (IA) demonstrated significantly longer median progression-free survival (PFS; primary end point; 13.3 vs 4.4 months; P < .0001) and higher overall response rate (ORR) with ide-cel vs SRs. At final PFS analysis (median follow-up, 30.9 months), ide-cel further improved median PFS vs SRs (13.8 vs 4.4 months; hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.38-0.63). PFS benefit with ide-cel vs SRs was observed regardless of number of prior lines of therapy, with greatest benefit after 2 prior lines (16.2 vs 4.8 months, respectively). ORR benefit was maintained with ide-cel vs SRs (71% vs 42%; complete response, 44% vs 5%). Patient-centric design allowed crossover from SRs (56%) to ide-cel upon progressive disease, confounding overall survival (OS) interpretation. At IA of OS, median was 41.4 (95% CI, 30.9 to not reached [NR]) vs 37.9 (95% CI, 23.4 to NR) months with ide-cel and SRs, respectively (HR, 1.01; 95% CI, 0.73-1.40); median OS in both arms was longer than historical data (9-22 months). Two prespecified analyses adjusting for crossover showed OS favoring ide-cel. This trial highlighted the importance of individualized bridging therapy to ensure adequate disease control during ide-cel manufacturing. Ide-cel improved patient-reported outcomes vs SRs. No new safety signals were reported. These results demonstrate the continued favorable benefit-risk profile of ide-cel in early-line and TCE R/RMM. This trial was registered at www.ClinicalTrials.gov as #NCT03651128.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ailawadhi S, Arnulf B, Patel K, et al. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood. 2024. PMID: 39197072. doi:10.1182/blood.2024024582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。